GlaxoSmithKline Pharmaceuticals Limited — PPTs, 13-05-2025: Investor Presentation

1. Financial Highlights:

Revenue grew 9% to ₹3,723 Cr for FY25, driven by +8% volume growth in General Medicines and 12% in Pediatric Vaccines (Boostrix, Varilrix, Havrix). PAT surged 32% to ₹915 Cr on a 5% margin expansion to 25%. EBITDA rose 30% to ₹1,169 Cr with a 31% margin, reflecting better gross margins and cost efficiencies. Q4 revenue increased 6% to ₹966 Cr, with PAT up 36% to ₹260 Cr and EBITDA margin expanding 620 bps to 34%. ROCE improved sharply to 64%. Operating costs benefited from reorganization and digital initiatives, while working capital and cash flow remained strong.

2. Strategic Initiatives & Growth Drivers:

Growth focused on specialty respiratory care leveraging Ellipta device and efficacy data for Nucala in severe asthma. Pediatric and adult vaccination businesses expanded via digital innovation, stronger HCP engagement, and partnerships. Shingrix category growth accelerated through awareness campaigns and pilot clinics. Digital transformation and cost-efficiency programs boosted field productivity (+9%) and SG&A leverage.

3. Business Developments:

Expanded adult immunization ecosystem through collaboration with Fortis Escorts Delhi. Deepened digital and face-to-face HCP and patient engagement (~3.6 Mn touchpoints). Initiated clinical studies to differentiate respiratory portfolio and elevated COPD and severe asthma disease management. Launched vaccination cards and education initiatives supporting Shingrix adoption.

4. Market Position & Competitive Advantage:

Maintains No.1 brand status in IPM with leadership in cefuroxime, mupirocin, and SITT respiratory categories. Pediatric vaccines lead with ~21.2% market share, supported by strong brands (Havrix, Varilrix). Respiratory segment differentiation backed by real-world efficacy and device innovation enhances competitive edge. Recognized for workplace excellence and operational sustainability.

5. Investor Implications:

Strong revenue and margin momentum plus digital transformation and specialty focus indicate positive growth potential. Leadership in vaccines and respiratory segments supports sustainable scaling. Execution risks include competition and market penetration challenges, but efficient cost management and improving working capital offer confidence in cash flows and returns.